# BigHat Biosciences

> BigHat Biosciences is a San Mateo biotech using machine learning and a high-speed wet lab to design safer, more effective therapeutic antibodies. Its Milliner platform iterates between in-silico design and physical molecules in days, optimizing biologics across binding, stability, immunogenicity and developability for partners like Merck and Johnson & Johnson.

- **Founded:** 2019
- **Headquarters:** San Mateo, California, United States
- **Founders:** Mark DePristo (Co-Founder & CEO), Peyton Greenside (Co-Founder & Chief Scientific Officer)
- **Team size:** approx. 97 employees
- **Products:** Milliner Platform, Partnership Programs, Internal Pipeline
- **Notable:** Raised over $174M in total funding across Seed, Series A and Series B, Signed strategic AI-antibody partnerships with both Merck and Johnson & Johnson, Built a closed-loop ML + wet-lab platform (Milliner) capable of cycle times measured in days

## Products & services

- **Milliner Platform** — An ML-guided antibody design platform that tightly couples computational design with a high-throughput wet lab to optimize multiple antibody properties simultaneously - affinity, stability, immunogenicity, developability.
- **Partnership Programs** — Strategic collaborations with pharmaceutical partners to design novel antibodies against agreed-upon targets, including bispecifics, multi-specifics, VHH and next-gen formats.
- **Internal Pipeline** — BigHat-led therapeutic programs in undisclosed disease areas leveraging the Milliner platform.

## Achievements

- Raised over $174M in total funding across Seed, Series A and Series B
- Signed strategic AI-antibody partnerships with both Merck and Johnson & Johnson
- Built a closed-loop ML + wet-lab platform (Milliner) capable of cycle times measured in days

## Latest updates

- **2024-04** — Announced strategic collaboration with Johnson & Johnson Innovative Medicine for ML-driven antibody discovery.
- **2023** — Expanded multi-program partnership with Merck for AI-powered antibody discovery.
- **2022-07** — Closed $75M Series B led by Section 32 to scale the Milliner platform.

## Links

- Website: https://bighatbio.com
- LinkedIn: https://www.linkedin.com/company/bighat-biosciences
- Twitter/X: https://twitter.com/bighatbio

---

Profile page: https://yespress.io/bighat-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-05-19